Universal Ibogaine Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IBOGF research report →
Price Chart
About the company
Universal Ibogaine Inc. , a life sciences enterprise, focuses on developing, acquiring, and operating addiction treatment centers across Canada. The company is additionally preparing to launch clinical trials aimed at researching ibogaine's potential therapeutic applications for addiction.
- CEO
- Nicholas Peter Karos
- IPO
- 2022
- Employees
- 7
- HQ
- Calgary, AB, CA
Get TickerSpark's AI analysis on IBOGF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $31.29K
- P/E
- -0.50
- PEG
- -0.01
- P/S
- 0.67
- P/B
- 1.17
- EV/EBITDA
- -2.50
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- 23.67%
- Net Margin
- -88.01%
- ROE
- -149.60%
- ROIC
- 15.14%
Latest fiscal year · YoY change
- Revenue
- $1.07M+0.0%
- Gross Profit
- $1.07M+0.0%
- Op Income
- $497.15K
- Net Income
- $-10,496,202-171.4%
- EPS
- $-0.06-82.8%
- OCF Growth
- -33.3%
- FCF Growth
- -36.3%
- 52W High
- $0.35
- 52W Low
- $0.00
- 50D MA
- $0.02
- 200D MA
- $0.02
- Beta
- 4.38
- RSI (14)
- 35
- Avg Volume
- 202.41K
No earnings-call transcripts are available for IBOGF yet.
- Free Float
- 96.9%
- Shares Outstanding
- 312.86M
- Float Shares
- 303.14M
Our IBOGF coverage
Recent articles, reports, and earnings notes.
No research on IBOGF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate IBOGF report →Universal Ibogaine provides Bi-weekly Default Status Report on 2025 year-end filings and update on Restructuring process
thenewswire.com · Jan 19
Universal Ibogaine provides Bi-weekly Default Status Report on 2025 year-end filings and update on Restructuring process
thenewswire.com · Jan 2
Universal Ibogaine Provides Bi-weekly Default Status Report on 2025 Year-end Filings and Update on Restructuring Process
thenewswire.com · Dec 18
Universal Ibogaine advises further on application for Management Cease Trade Order
thenewswire.com · Dec 2
Universal Ibogaine Advises of Filing Application for Management Cease Trade Order
thenewswire.com · Nov 25
Universal Ibogaine Provides Corporate Update
thenewswire.com · Oct 28
Universal Ibogaine Announces Board Changes
thenewswire.com · Sep 23
Universal Ibogaine Announces Results of the Annual Meeting of Shareholders
thenewswire.com · Sep 14
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.